Stockreport

ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update

ZyVersa Therapeutics, Inc.  (ZVSA) 
PDF KEY BUSINESS HIGHLIGHTS Phase 2a clinical trial for Cholesterol Efflux Mediatorâ„¢ VAR 200 in patients with diabetic kidney disease expected to begin Q1-2025.New Obesit [Read more]